Do you know which fingolimod product your patients are actually receiving?

There are currently 12 generic fingolimod products listed on DailyMed,1 which pharmacies can switch your Gilenya® (fingolimod) capsules patients to without your consent. They can then be switched among the generics as pharmacies see fit. This could lead to inconsistencies in what your patients are actually receiving and can cause significant increases in co-pay costs.

This wouldn't happen with TASCENSO ODT ® (fingolimod) because it is not substitutable at the pharmacy level.2

TASCENSO ODT is a treatment for patients with MS who want to remain on fingolimod treatment while benefitting from Cycle Vita™, which provides individualized product support* as unique as your patients.
Tascenso Dissolve Icon


TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.3

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya®**
  • A similar lowering of lymphocyte counts and effect on heart rate as Gilenya®4
  • Not a generic2
  • Not substitutable at the pharmacy level2
  • Each and every batch tested
  • Dissolves on the tongue in seconds
  • Taken once daily, with or without food and with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
Find out more
Tascenso Care Icon


We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated hub support program, which delivers individualized product support* at every step. Including:

  • $0 Co-pay Assistance Program: Commercially insured eligible patients may pay as little as $0
  • Bridge Program: For patients taking another fingolimod treatment, a free supply of TASCENSO ODT is available to ensure the continuation of therapy while Cycle Vita secures appropriate benefit verification and prior authorization, if necessary
  • TASCENSO Time Program: Access to in-home first dose observation and baseline assessments as necessary
  • Hub Support: Including financial, logistics and medication adherence support
Find out more


Find out more about the orally disintegrating tablet, including how it can be taken.


Read more about our dedicated hub support program, Cycle Vita.

Efficacy and Safety

See the efficacy and safety data, and learn more about its bioequivalence.


Download the enrollment form to enroll your patients on TASCENSO ODT.

“There is no additional safety or efficacy data required to bring… [generics] onto the marketplace and there can be differences… [which] can cause therapeutic gaps or mishaps for patients.”

Dr Scagnelli, MD, Raleigh Neurology

John Scagnelli

Download an enrollment form to enroll a patient in TASCENSO ODT. Complete all the required fields either digitally or by printing it. You can then either fax the form to Cycle Vita at + 1 (888) 385-8482 or email it to

Download Form


1. National Library of Medicine (2023) Daily Med search results for fingolimod. Accessed August 22nd 2023. Available: 

2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed August 22nd 2023. Available:

3. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.

4. Data on File: REF-00075

* Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

** Gilenya® is a registered trademark of Novartis AG.